Swiss Life Asset Management’s Cogent Biosciences COGT Stock Holding History

Swiss Life Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$283K	Buy	+7,317	New	+$256K	﹤0.01%	1304

Other funds holding COGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Swiss Life Asset Management's COGT Position: Q2 2026 in Review

Swiss Life Asset Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 7,317 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #1304 among its holdings.

159 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Swiss Life Asset Management held 7,317 shares of Cogent Biosciences worth $283K as of Q2 2026.
Cogent Biosciences was a new Swiss Life Asset Management position in Q2 2026.
Cogent Biosciences made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #1304 holding.
159 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.